Pakistan calls for improved public healthcare access and facilities
This article was originally published in Scrip
Pakistan's federal minister for health has called for changes in the national healthcare system to improve access and facilities for the general public. Ijaz Jackrani said "positive changes" were needed to ensure health delivery was visible and easy to access for the public, while the health secretary said present regulations were outdated and needed to be changed. As part of the improvements the minister called for a focus on controlling the spread of hepatitis B and C through an awareness campaign, as well as for action against unqualified doctors operating in the country. The ministry hopes improving public health delivery services will help reduce poverty in the country.
You may also be interested in...
The Indian pharmaceutical sector is recognised for its entrepreneurial spirit. Many companies have crafted successful business strategies by offering API manufacturing, drug discovery, CRAMS and other services to global pharmaceutical customers. Others market their products overseas while leveraging growth opportunities on their home turf. The following five domestic companies are well worth watching in 2011.
The Swedish biotech firm Active Biotech has appointed Dr Helén Tuvesson as its new chief scientific officer, effective 1 April. Dr Tuvesson has been with the company since 1998, working in preclinical development, R&D management and most recently within the senior management team. She will report to president and CEO Tomas Leanderson.
Affimed Therapeutics (Germany) has appointed Dr Adi Hoess as its new chief commercial officer. Effective immediately, Mr Hoess will focus on commercial and strategic management and business development, complimenting his previous senior management and business development roles at Jenowis, Carl Zeiss Jena, MorphoSys and Jerini. His appointment also coincides with the continued development of the company's lead product candidate, AFM13, for Hodgkin's lymphoma, which entered a Phase I clinical trial last November (scripintelligence.com, 15 November 2010).